Building Tesorai - an interview with Peter

Tanja Janko with the ASEF spoke with Peter about the creation of Tesorai and the future of molecular analysis.
ON THIS PAGE

The American Slovenian Education Foundation (ASEF) is a US-based non-profit that promotes Slovenian heritage through academic excellence, character development, and dedication to service. ASEF’s Tanja Janko interviewed Peter Cimermancic, Tesorai Co-Founder and CAIO, about his training, his transition to industry, and the science behind Tesorai.

Listen on Buzzsprout: https://www.buzzsprout.com/1753090/episodes/15398225 

Listen on YouTube: https://youtu.be/Kb8Y-sLt_x0?si=gBhIk8hh5uFd9YmS 

Podcast timestamps

0:50 What initially drew you to the field you are currently in, and what continues to motivate you in your research?

2:41 Early career and how would you compare your experience studying in Slovenia vs. abroad? 

5:53 How and why did you decide to transition to the industry?

8:39 What prompted you to start your own business instead of staying in academia / staying in the industry(big tech)?

11:14 Protein structure prediction is arguably one of the most successful applications of deep learning in computational biology - can you tell us why is knowing 3D structure of proteins important?

16:05 Why is mapping the sequence-function of a given protein a challenge?

18:37 What kind of data sets (labeled / unlabeled) are used in modeling and what are some advantages/disadvantages of both?

20:56 Talking about Peter’s publication (Cimermancic P, et al., CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. J Mol Biol. 2016 Feb 22;  https://doi.org/10.1016/j.jmb.2016.01.029 ) 

What defines a cryptic site in proteins, and how does it differ from traditional binding pockets?

23:10 What methods are employed to identify cryptic sites, both experimentally and computationally?

25:54 What impact did the prediction of cryptic sites have on the "druggable" human proteome?

26:42 What is TesorAI, what is the goal of the products and what are the plans for the future?

33:46 About TesorAI products

35:36 where do you get data to train models

36:32 Data in academic computational biology

37:22 What are the emerging trends and future directions in computational biology that are bound to make a significant impact on healthcare in the coming years? 

40:21 Challenges in the field

41:35 How do you see the Slovenian startup space fitting in this field?

42:58 As our understanding of the human genome and proteome grows, what are the ethical considerations surrounding genetic engineering, gene editing, and personalized medicine? How do we balance the potential benefits of such technologies with concerns about privacy, equity, and unintended consequences? 

46:00 Reverse aging and biological destiny

49:20/50:50 Book recommendations

Explore more resources

Technical explainers, publications, guides, and perspectives on proteomics data analysis and biological discovery.
View all resources
Publication

Publications

Single-cell foundation models benefit from cross-modal training: adding proteomics data beats parameter scaling

Fine-tuning a single-cell foundation model on proteomics data matches or beats scaling to models over 40x larger — showing multimodal training can outperform parameter scaling alone.

Pan-Cancer Atlas resource card graphic

Building a Pan-Cancer Atlas of Therapeutic T Cell Targets

How NYU researchers used large-scale immunopeptidomics and AI-enabled peptide identification to identify 28,446 tumor-specific antigens and accelerate therapeutic target discovery.

Guangyuan (Frank) Li, PhD, NYU Langone Health
FDR, MBR, and Immunopeptidomics guide resource card graphic

FDR, Match-Between-Runs, and Immunopeptidomics: A Plain-Language Guide

Three concepts that determine whether you can trust your proteomics results — and what to look for when evaluating any search engine.